177 related articles for article (PubMed ID: 32539654)
1. What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer.
Whisenant MS; Williams LA; Garcia Gonzalez A; Mendoza T; Shi Q; Cleeland C; Zhang J; Heymach J; Simon G
JCO Oncol Pract; 2020 Oct; 16(10):e1151-e1160. PubMed ID: 32539654
[TBL] [Abstract][Full Text] [Related]
2. Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
Williams LA; Whisenant MS; Mendoza TR; Haq S; Keating KN; Cuffel B; Cleeland CS
Qual Life Res; 2018 Dec; 27(12):3229-3241. PubMed ID: 30187393
[TBL] [Abstract][Full Text] [Related]
3. Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory.
Mendoza TR; Wang XS; Lu C; Palos GR; Liao Z; Mobley GM; Kapoor S; Cleeland CS
Oncologist; 2011; 16(2):217-27. PubMed ID: 21285393
[TBL] [Abstract][Full Text] [Related]
4. Capturing the patient's experience: using qualitative methods to develop a measure of patient-reported symptom burden: an example from ovarian cancer.
Williams LA; Agarwal S; Bodurka DC; Saleeba AK; Sun CC; Cleeland CS
J Pain Symptom Manage; 2013 Dec; 46(6):837-45. PubMed ID: 23615044
[TBL] [Abstract][Full Text] [Related]
5. Validation and Application of the MD Anderson Symptom Inventory for Traditional Chinese Medicine (MDASI-TCM).
Li Z; Shi Q; Liu M; Jia L; He B; Yang Y; Liu J; Lin H; Lin HK; Li P; Wang XS
J Natl Cancer Inst Monogr; 2017 Nov; 2017(52):. PubMed ID: 29140491
[TBL] [Abstract][Full Text] [Related]
6. Assessment of baseline symptom burden in treatment-naïve patients with lung cancer: an observational study.
Mendoza TR; Kehl KL; Bamidele O; Williams LA; Shi Q; Cleeland CS; Simon G
Support Care Cancer; 2019 Sep; 27(9):3439-3447. PubMed ID: 30661202
[TBL] [Abstract][Full Text] [Related]
7. What symptoms are important to patients? Developing a symptom burden measure for women with breast cancer.
Whisenant MS; Strunk FA; Tripathy D; Williams LA
Support Care Cancer; 2019 Dec; 27(12):4639-4647. PubMed ID: 30937601
[TBL] [Abstract][Full Text] [Related]
8. Measuring symptom burden in patients with cancer during a pandemic: the MD Anderson symptom inventory for COVID-19 (MDASI-COVID).
Williams LA; Whisenant MS; Mendoza TR; Peek AE; Malveaux D; Griffin DK; Ponce DA; Granwehr BP; Sheshadri A; Hutcheson KA; Ali SM; Peterson SK; Heymach JV; Cleeland CS; Subbiah IM
J Patient Rep Outcomes; 2023 May; 7(1):48. PubMed ID: 37237077
[TBL] [Abstract][Full Text] [Related]
9. Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN).
Wang XS; Shi Q; Williams LA; Cleeland CS; Garcia-Gonzalez A; Chen TY; Shahid DR; Ramirez PT; Iniesta MD; Siverand AM; Meyer LA
Gynecol Oncol; 2019 Mar; 152(3):492-500. PubMed ID: 30876494
[TBL] [Abstract][Full Text] [Related]
10. Association between the patients' symptom burden and their family caregivers' benefit finding in non-small cell lung cancer receiving combined chemotherapy.
Ma L; Zhu K; Shi C; Chen X; Gao Y; Cai C; Wang Y
Support Care Cancer; 2023 Feb; 31(2):148. PubMed ID: 36729306
[TBL] [Abstract][Full Text] [Related]
11. Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer.
Sailors MH; Bodurka DC; Gning I; Ramondetta LM; Williams LA; Mendoza TR; Agarwal S; Sun CC; Cleeland CS
Gynecol Oncol; 2013 Aug; 130(2):323-8. PubMed ID: 23685012
[TBL] [Abstract][Full Text] [Related]
12. Symptom recovery after thoracic surgery: Measuring patient-reported outcomes with the MD Anderson Symptom Inventory.
Fagundes CP; Shi Q; Vaporciyan AA; Rice DC; Popat KU; Cleeland CS; Wang XS
J Thorac Cardiovasc Surg; 2015 Sep; 150(3):613-9.e2. PubMed ID: 26088408
[TBL] [Abstract][Full Text] [Related]
13. The validity and utility of the M. D. Anderson Symptom Inventory in patients with breast cancer: evidence from the symptom outcomes and practice patterns data from the eastern cooperative oncology group.
Mendoza TR; Zhao F; Cleeland CS; Wagner LI; Patrick-Miller LJ; Fisch MJ
Clin Breast Cancer; 2013 Oct; 13(5):325-34. PubMed ID: 23816985
[TBL] [Abstract][Full Text] [Related]
14. The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study.
Iyer S; Roughley A; Rider A; Taylor-Stokes G
Support Care Cancer; 2014 Jan; 22(1):181-7. PubMed ID: 24026981
[TBL] [Abstract][Full Text] [Related]
15. Reliability and validity of the M. D. Anderson Symptom Inventory-Spine Tumor Module.
Armstrong TS; Gning I; Mendoza TR; Vera-Bolanos E; Gilbert MR; Rhines LD; Weinberg JS; Sanchez-Williams G; Levin V; Burton AW; Cleeland C
J Neurosurg Spine; 2010 Apr; 12(4):421-30. PubMed ID: 20367379
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of patient-reported symptom interference in patients with late-stage lung cancer.
Barney BJ; Wang XS; Lu C; Liao Z; Johnson VE; Cleeland CS; Mendoza TR
Qual Life Res; 2013 Oct; 22(8):2143-50. PubMed ID: 23371797
[TBL] [Abstract][Full Text] [Related]
17. Psychometric Validation of the M. D. Anderson Symptom Inventory-Head and Neck Module in the Spanish Language.
Sánchez D; Chala A; Alvarez A; Payan C; Mendoza T; Cleeland C; Sanabria A
J Pain Symptom Manage; 2016 Jun; 51(6):1055-61. PubMed ID: 26899822
[TBL] [Abstract][Full Text] [Related]
18. Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module.
Tanaka S; Sato I; Takahashi M; Armstrong TS; Cleeland CS; Mendoza TR; Mukasa A; Takayanagi S; Narita Y; Kamibeppu K; Saito N
Jpn J Clin Oncol; 2020 Jul; 50(7):787-793. PubMed ID: 32280995
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy.
Wang XS; Shi Q; Williams LA; Mao L; Cleeland CS; Komaki RR; Mobley GM; Liao Z
Brain Behav Immun; 2010 Aug; 24(6):968-74. PubMed ID: 20353817
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy.
Wang XS; Srour SA; Mendoza T; Whisenant M; Subbiah I; Gonzalez E; Kamal M; Shen SE; Cleeland C; Kebriaei P; Rezvani K; Neelapu S; Ahmed S; Shpall E
Br J Haematol; 2023 May; 201(4):738-746. PubMed ID: 36733986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
